| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3009 | Human BCMA-CHO-K1 Stable Cell Line | 2 vials | $2950 | Order |
| Catalog Number | C3009 |
|---|---|
| Cell Line Name | Human BCMA-CHO-K1 Stable Cell Line |
| Accession Number | AAH58291.1 |
| Host Cell | Adherent CHO-K1 |
| Quantity | Two vials of frozen cells (2x106 per vial) |
| Culture Medium | DMEM with 10% FBS, 4 µg/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen upon receipt |
| Product Datasheet: | Download PDF |
Detection of human BCMA expression on human BCMA-CHO-K1 stable cells using a monoclonal antibody specific for human BCMA (BioLegend Cat #357504)
B-cell maturation antigen (BCMA), also known as TNFRSF17 (Tumor Necrosis Factor Receptor Superfamily Member 17), is a transmembrane glycoprotein belonging to the TNF receptor superfamily. It is primarily expressed on the surface of mature B cells, particularly plasma cells, and plays a crucial role in B cell maturation and survival. BCMA is involved in the regulation of B cell development, survival, and differentiation, especially in the context of antibody-secreting plasma cells. Its interaction with its ligands, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), activates downstream signaling pathways such as NF-KB, promoting B cell proliferation, survival, and antibody production. BCMA expression is up-regulated in certain hematological malignancies, particularly multiple myeloma (MM). In MM, malignant plasma cells overexpress BCMA, making it a promising target for therapeutic interventions aimed at treating this disease. Various strategies have been developed to target BCMA, including monoclonal antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies. These approaches aim to specifically target BCMA-expressing cells, inducing cytotoxicity and immune-mediated destruction of malignant plasma cells.
Hosen N, Matsuoka Y, Kishida S, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 26(9):2135-2141. 2012.
Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 7(11):1187-1199. 2015.
Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 19(12):1641-1653. 2018.
Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 129(6):2210-2221. 2019.